2024 advanced therapy industry report

Insights from the frontlines of advanced therapy

Dive into the findings from our 2024 state of the advanced therapy industry report, highlighting important trends and insights from 376 industry stakeholders across the cell and gene therapy market. Our survey, expanded this year to capture diverse viewpoints, sheds light on optimism in the industry, growth strategies, and pressing challenges.

We found that nearly 90% of leaders feel positive/very positive about the next 12–18 months. Positivity remains high among all stakeholders suggesting expected ongoing progress and confidence in the market. More than 80% of respondents had a favorable outlook for gene therapies and 77% for autologous cell therapies. As organizations invest in their AT portfolios, results showed rising interest in novel treatment modalities with 25% of ATDs looking into RNA-based therapies.

Propel your AT business toward transformative growth

Overall, results show a sector poised for transformative growth, driven by optimism and strategic innovation. Stakeholders industry-wide share a positive outlook, fueled by scientific advancements. With reimbursement hurdles, scalability of manufacturing operations, and regulatory ambiguities as ongoing challenges, the industry is increasingly adopting collaborative approaches and using digital tech to enhance automation for operational efficiencies and innovation.

Embracing innovative payment models, enhancing patient education, and establishing robust clinical trial designs are strategies needed for the AT sector to overcome financial, adherence, and regulatory challenges. As the AT sector approaches a crossroads in its growth, the industry’s ability to navigate these challenges will define its future in revolutionary treatment paradigms.